This study looks at whether a medicine called camizestrant can help people with early breast cancer that is ER+ and HER2-. The goal is to see if it works better than standard treatments like aromatase inhibitors or tamoxifen. Patients in the study are those who have finished their initial treatment and are at risk for the cancer coming back. The treatment will last for up to 7 years.
The trial's ID is NCT05952557. This is a Phase 3 study, which means it is testing how well the treatment works and how safe it is. It is regulated by the FDA and aims to include about 5,500 participants.
Who can join
Men and women aged 18 and older can join. Participants should have early-stage ER+/HER2- breast cancer and have completed their initial treatment. They should be at risk for the cancer returning. Some people cannot join, including those with advanced breast cancer, certain heart issues, or those who are pregnant or breastfeeding. The trial team will confirm if each person is eligible.
Condition
Breast Cancer, Early Breast Cancer
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into two groups. One group will receive standard endocrine therapy, which may include medications like tamoxifen or an aromatase inhibitor, possibly along with abemaciclib. The other group will take camizestrant, also possibly with abemaciclib. Everyone will receive treatment for up to 7 years.
Where
This trial is enrolling at 148 locations. Recruiting sites are listed first.
Director of the Breast Cancer Center at NYU Langone’s Perlmutter Cancer Center. Treats breast cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Inaugural Jeffrey F. Moley Professor of Endocrine and Oncologic Surgery, WashU. Treats breast cancer. A surgeon is the doctor who removes cancer with an operation (adults). Recognized at state, national or international level.
Microsurgical breast reconstruction specialist, MSK. Treats breast cancer and mouth cancer. Offers microsurgical breast reconstruction, head and neck reconstruction and abdominal wall reconstruction.